Inside the research
Perrigo Company plc
PRGO Research profile · latest available data
Price overview
$15.42
▲ +0.74 (+5.0%)
| 52w hi | $21.03 |
|---|---|
| 52w lo | $8.83 |
| Vol | 4.27M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.15
| Short | +0.55 |
|---|---|
| Medium | +0.14 |
| Long | -0.61 |
computed 2026-09-27
Key fundamentals
Perrigo Company plc
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $2.13B |
|---|---|
| Enterprise value | $5.22B |
| Forward P/E | 6.43x |
| EV / EBITDA | 8.47x |
| P / S (ttm) | 0.52x |
| Profit margin | -41.9% |
| Return on equity | -48.7% |
| Revenue growth | -3.2% |
| Debt / equity | 138.18 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.13 | |
| Sector | +0.08 | |
| Technical | +0.10 | |
| Earnings | +0.00 | |
| Sentiment | +0.39 |
macro × 1.00 · 2026-09-27
Business overview
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Risk Metrics
| Beta vs SPX | 0.87 |
|---|---|
| Corr SPX | 0.29 |
| Annual vol | 47.3% |
| Annual ret | -17.0% |
| Sharpe | -0.36 |
| Max DD | -68.6% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-07-06 | Officer / Director Change | read |
| 2026-06-30 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-06-08 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-05-05 | Officer / Director Change, Shareholder Vote… | read |
| 2026-04-30 | Acquisition / Disposition, Reg FD Disclosure… | read |
| 2026-04-22 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-23 | Material Agreement, Material Obligation… | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2025-11-05 | Earnings Release, Reg FD Disclosure | read |
| 2025-08-06 | Earnings Release, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 95.9% |
| HHI | 3,106 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $88.66M | 8.53M |
| AQR Capital Management | $35.26M | 3.48M |
| Millennium Management | $30.99M | 2.98M |
| Capital Research / Capital World | $16.20M | 1.56M |
| Fidelity / FMR LLC | $4.09M | 394.03K |
| Citadel Advisors | $4.07M | 391.78K |
| Bridgewater Associates | $3.37M | 324.08K |
| T. Rowe Price Group | $90.40K | 8.70M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2014–2025 · 11 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $4.66B | +19.7% | |
| Gross profit | $1.49B | +0.3% | |
| Operating income | $151.90M | -15.2% | |
| Net income | -$171.80M | -30.9% | |
| Cash from ops | $405.50M | -2.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $14.81 | $15.69 | $14.22 | $15.42 | 4.27M |
| Sep 24 | $13.87 | $15.10 | $13.84 | $14.68 | 7.73M |
| Sep 23 | $14.22 | $14.46 | $13.76 | $13.84 | 1.46M |
| Sep 22 | $14.20 | $14.45 | $14.16 | $14.31 | 2.32M |
| Sep 21 | $14.00 | $14.22 | $13.61 | $14.13 | 1.71M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →